Physiomics plc (PYC), the AIM-quoted computational drug development specialist, held its Annual General Meeting on 5 November 2026 and confirmed that all ten resolutions put to shareholders were duly passed. Following the meeting, the company announced the issue of 14,000,000 new Ordinary Shares to three directors as remuneration in lieu of cash, a structure first agreed by the Board on 30 June 2026. The share issuance will increase the company's total voting rights to 467,208,718 shares upon admission to AIM, expected on or around 11 November 2026.

Key Points

  • Physiomics plc (PYC), AIM-listed computational modelling and drug development services company
  • All ten AGM resolutions passed at the meeting held on 5 November 2026 at Strand Hanson, Mayfair, London
  • 14,000,000 new Ordinary Shares issued to directors at 0.50 pence per share; enlarged share capital of 467,208,718 shares expected from 11 November 2026
  • Investors should watch for confirmation of AIM admission on or around 11 November 2026 and any further director remuneration disclosures

All Ten Resolutions Approved at Physiomics AGM on 5 November 2026

Physiomics confirmed that every resolution at its Annual General Meeting, held at 10.30 a.m. GMT at Strand Hanson's offices in Mayfair, was passed by shareholders. Across the ten resolutions, votes cast in favour ranged from approximately 31.9 million to 34.1 million shares, with the total shares voted at each resolution standing at 34,526,617. The company held 453,208,718 shares in issue as of 6:30 p.m. on 4 November 2026 and confirmed it holds no shares in treasury. The announcement states that no resolutions were defeated and none required a casting vote from the chairman.

Directors Receive Shares at 0.50 Pence Each as Part of Board Remuneration Arrangements

Following the AGM, three directors will receive new Ordinary Shares in lieu of part of their cash remuneration, as originally agreed on 30 June 2026. Chairman Nick Tulloch will receive 4,000,000 new Ordinary Shares representing remuneration of £20,000, while Executive Director Mike Whitlow and Finance Director Ian Bagnall will each receive 5,000,000 new Ordinary Shares representing remuneration of £25,000 apiece. All shares are issued at 0.50 pence per share, being the closing price on 28 April 2026, the day before the directors joined the Board. The aggregate issuance totals 14,000,000 shares with a combined value of £70,000.

AIM Admission of 14 Million New Shares Expected on 11 November 2026

Physiomics has applied for the 14,000,000 new Ordinary Shares to be admitted to trading on AIM, with admission expected at 8:00 a.m. on 11 November 2026. The new shares will rank pari passu in all respects with existing Ordinary Shares. Upon admission, the company's enlarged share capital will comprise 467,208,718 Ordinary Shares of 1 pence each, which also becomes the total number of voting rights. Shareholders are advised to use this figure as the denominator when calculating whether a notification obligation arises under the FCA's Disclosure Guidance and Transparency Rules.

Physiomics Serves Pharma Clients Using Proprietary Virtual Tumour Technology

Physiomics combines expertise in modelling and simulation, biostatistics, data science, and bioinformatics to support biotech and pharmaceutical companies through drug development. The company's proprietary Virtual Tumour technology and bespoke computational models have informed more than 140 commercial projects, covering over 125 targets and drugs. Clients named in the announcement include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics, and Cancer Research UK. The director share-for-cash remuneration structure may reflect the company's approach to conserving cash resources, though the announcement does not provide explicit commentary on this point.